Bemarituzumab (FPA 144), a specific anti-FGFR2 monoclonal antibody, was tested in a phase I monotherapy study and led to an ORR of 18% (5 out of 28 patients) in patients with chemorefractory GC, FGFR2 amplification and FGFR2b overexpression [74]. Here, FGFR2 is linked to gastric cancer.